Malarone (Proguanil Hydrochloride, Atovaquone)

The combination works by targeting two different biochemical pathways in the malaria parasite. Atovaquone blocks mitochondrial electron transport, halting energy production, while proguanil is converted to cycloguanil, which inhibits the enzyme dihydrofolate reductase, disrupting DNA synthesis. Together, these actions produce a synergistic effect that rapidly kills the parasite and limits the development of resistance.

The specific dose of Malarone is determined by the prescribing healthcare professional based on the indication, patient age, weight, and renal function. For malaria prophylaxis, the medication is typically started 1–2 days before travel, taken daily during exposure, and continued for 7 days after leaving the endemic area. For treatment, the regimen differs and must be prescribed by a qualified clinician.

Safety data for Malarone during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Healthcare providers should weigh the potential benefits against possible risks before prescribing it to pregnant or nursing women. In many cases, alternative antimalarial agents with more established safety profiles may be preferred.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Malarone. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements if applicable), and assistance with import documentation.

Compared with older agents such as chloroquine or mefloquine, Malarone offers a higher barrier to resistance due to its dual‑target mechanism. It is generally better tolerated than mefloquine, which can cause neuropsychiatric effects, and it remains effective in many regions where chloroquine resistance is widespread. However, cost and availability may differ, and clinicians consider local resistance patterns when selecting therapy.

Malarone tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing it in humid environments such as bathrooms. Do not freeze or refrigerate the tablets, as this could affect their stability.

Malarone is taken orally with a full glass of water, preferably with food or a milky drink to enhance absorption of atovaquone. The tablets should be swallowed whole and not chewed or crushed. For prophylaxis, the dose is taken once daily; for treatment, the prescribed regimen may involve multiple daily doses for a short course.

The most concerning adverse events include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, significant liver injury manifested by elevated transaminases or jaundice, and hematologic abnormalities like neutropenia or anemia. Patients should seek immediate medical attention if they develop rash, yellowing of the skin or eyes, or unexplained bruising or bleeding.

Malarone is contraindicated in individuals with known hypersensitivity to atovaquone, proguanil, or any component of the formulation. It should be used with caution, or avoided, in patients with severe renal impairment, significant hepatic disease, or those who are pregnant or breastfeeding without a clear benefit. Children weighing less than 5 kg are also not eligible for this medication.